Hume Jocelyn, Sweeney Emma L, Lowry Kym, Fraser Chris, Clark Julia E, Whiley David M, Irwin Adam D
The University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Central Microbiology, Pathology Queensland, Brisbane, QLD, Australia.
Front Pediatr. 2023 May 30;11:1180392. doi: 10.3389/fped.2023.1180392. eCollection 2023.
Cytomegalovirus (CMV) is a ubiquitous virus which causes a mild illness in healthy individuals. In immunocompromised individuals, such as children receiving haematopoietic stem cell transplantation, CMV can reactivate, causing serious disease and increasing the risk of death. CMV can be effectively treated with antiviral drugs, but antiviral resistance is an increasingly common complication. Available therapies are associated with adverse effects such as bone marrow suppression and renal impairment, making the choice of appropriate treatment challenging. New agents are emerging and require evaluation in children to establish their role. This review will discuss established and emerging diagnostic tools and treatment options for CMV, including antiviral resistant CMV, in children undergoing haematopoietic stem cell transplant.
巨细胞病毒(CMV)是一种普遍存在的病毒,在健康个体中会引发轻微疾病。在免疫功能低下的个体中,如接受造血干细胞移植的儿童,CMV可能会重新激活,导致严重疾病并增加死亡风险。CMV可用抗病毒药物有效治疗,但抗病毒耐药性是一种日益常见的并发症。现有疗法会产生诸如骨髓抑制和肾功能损害等不良反应,使得选择合适的治疗方法具有挑战性。新的药物正在出现,需要在儿童中进行评估以确定其作用。本综述将讨论接受造血干细胞移植的儿童中CMV(包括抗病毒耐药CMV)的既定和新兴诊断工具及治疗选择。